Marshall Wace LLP Cuts Stake in Cardlytics, Inc. (NASDAQ:CDLX)

Marshall Wace LLP trimmed its position in Cardlytics, Inc. (NASDAQ:CDLX - Free Report) by 75.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 207,064 shares of the company's stock after selling 646,889 shares during the period. Marshall Wace LLP owned approximately 0.41% of Cardlytics worth $768,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Tallon Kerry Patrick purchased a new stake in shares of Cardlytics in the fourth quarter worth approximately $37,000. Virtu Financial LLC purchased a new position in Cardlytics during the 4th quarter worth $62,000. SG Americas Securities LLC grew its stake in shares of Cardlytics by 38.2% in the 4th quarter. SG Americas Securities LLC now owns 19,490 shares of the company's stock worth $72,000 after acquiring an additional 5,392 shares in the last quarter. Intech Investment Management LLC grew its stake in shares of Cardlytics by 31.3% in the 4th quarter. Intech Investment Management LLC now owns 19,310 shares of the company's stock worth $72,000 after acquiring an additional 4,607 shares in the last quarter. Finally, Global Retirement Partners LLC lifted its position in shares of Cardlytics by 54.7% during the fourth quarter. Global Retirement Partners LLC now owns 19,800 shares of the company's stock valued at $73,000 after purchasing an additional 7,000 shares in the last quarter. Institutional investors own 68.10% of the company's stock.

Insiders Place Their Bets

In related news, CFO Alexis Desieno sold 24,778 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $84,245.20. Following the completion of the transaction, the chief financial officer now directly owns 140,948 shares in the company, valued at $479,223.20. The trade was a 14.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Amit Gupta sold 46,857 shares of Cardlytics stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $3.40, for a total transaction of $159,313.80. Following the sale, the chief executive officer now owns 418,637 shares of the company's stock, valued at approximately $1,423,365.80. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,938 shares of company stock worth $244,017 over the last 90 days. Corporate insiders own 4.40% of the company's stock.

Cardlytics Stock Performance

Cardlytics stock traded up $0.01 during midday trading on Wednesday, reaching $2.16. The stock had a trading volume of 2,044,538 shares, compared to its average volume of 1,031,669. The firm has a market capitalization of $112.70 million, a PE ratio of -0.35 and a beta of 1.30. Cardlytics, Inc. has a 12 month low of $1.22 and a 12 month high of $15.45. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. The firm's 50-day moving average price is $1.83 and its 200 day moving average price is $3.00.

Cardlytics (NASDAQ:CDLX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.01. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. As a group, research analysts predict that Cardlytics, Inc. will post -1.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on CDLX. Needham & Company LLC reiterated a "hold" rating on shares of Cardlytics in a research note on Thursday, March 13th. Evercore ISI cut their price objective on Cardlytics from $4.00 to $3.00 and set an "in-line" rating on the stock in a research report on Thursday, March 13th. Finally, Lake Street Capital reduced their price objective on Cardlytics from $5.00 to $3.00 and set a "hold" rating for the company in a research note on Thursday, March 13th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $6.42.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.